Insulin Resistance Predicts Later Cognitive Decline

Share this content:
Insulin Resistance Predicts Later Cognitive Decline
Insulin Resistance Predicts Later Cognitive Decline

MONDAY, April 10, 2017 (HealthDay News) -- Higher serum fasting insulin and insulin resistance predict poorer verbal fluency and a steeper decline in future verbal fluency, according to a study published online April 5 issue of Diabetes Care.

Laura L. Ekblad, M.D., from the University of Turku in Finland, and colleagues examined data from the Finnish nationwide, population-based Health 2000 Health Examination Survey and its 11-year follow-up, the Health 2011 study (3,695 participants; mean age at baseline, 49.3 years; 55.5 percent women). The authors sought to assess the roles of homeostatic model assessment of insulin resistance (HOMA-IR), fasting insulin and glucose, glycated hemoglobin, and high-sensitivity C-reactive protein (hs-CRP) as predictors of cognitive performance.

The researchers found that higher baseline HOMA-IR and fasting insulin levels were independent predictors of poorer verbal fluency performance (P = 0.0002 for both) and of a greater decline in verbal fluency over follow-up (P = 0.004 for both). Word-list learning and word-list delayed recall scores were not predicted by baseline HOMA-IR or insulin. There were no interactions between cognitive test performance and HOMA-IR and apolipoprotein E ε4 genotype, hs-CRP, or type 2 diabetes. Baseline levels of fasting glucose and hs-CRP levels were not associated with cognitive functioning.

"Prevention and treatment of insulin resistance might help reduce cognitive decline later in life," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »